{
  "id": "61f60157882a024a1000001e",
  "type": "factoid",
  "question": "What is the use of Atogepant?",
  "ideal_answer": "Atogepant is used for preventive treatment of migraine.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32297990",
    "http://www.ncbi.nlm.nih.gov/pubmed/33142014",
    "http://www.ncbi.nlm.nih.gov/pubmed/34521260",
    "http://www.ncbi.nlm.nih.gov/pubmed/34813050",
    "http://www.ncbi.nlm.nih.gov/pubmed/34407343",
    "http://www.ncbi.nlm.nih.gov/pubmed/33369482",
    "http://www.ncbi.nlm.nih.gov/pubmed/34788240"
  ],
  "snippets": [
    {
      "text": "Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34521260",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist for the preventive treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34521260",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Atogepant demonstrated treatment benefits as early as the first full day after treatment initiation, and sustained efficacy across each 4-week interval during the 12-week treatment period.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34521260",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Atogepant (Qulipta\u2122) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The drug is also in phase 3 clinical development for the preventive treatment of migraine in various other countries. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34813050",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This paper reviews the available data from RCTs to assess the clinical efficacy, safety, and tolerability profile of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine and atogepant for the prevention of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33369482",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Atogepant is a potent, selective, oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33142014",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Atogepant, a potent, selective antagonist of the calcitonin gene-related peptide receptor-in development for migraine prevention-is thus likely to be used by women taking oral contraceptives.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32297990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Atogepant for the Preventive Treatment of Migraine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34407343",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ember 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The dr",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34813050",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Atogepant for the Preventive Treatment of Migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34407343",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Atogepant for the Preventive Treatment of Migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788240",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Atogepant (Qulipta\u2122) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34813050",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist for the preventive treatment of migraine.METHODS: In the double-blind, phase 3 ADVANCE trial, participants with 4-14 migraine days/month were randomized to atogepant 10\u2009mg, 30\u2009mg, 60\u2009mg, or placebo onc",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34521260",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34813050",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of atogepant leading to this first approval for the preventive treatment of episodic migraine in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34813050",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "preventive treatment of migraine"
}